托法替布治疗类风湿关节炎患者主要不良心血管事件危险因素分析
多变量分析显示基线年龄、高血压及总胆固醇/高密度脂蛋白胆固醇比值与MACE风险显著相关;治疗24周后高密度脂蛋白胆固醇升高与未来MACE风险降低相关。
要点
- 传统心血管危险因素与托法替布治疗患者MACE风险相关,疾病活动度指标未见关联。
- 基线年龄、高血压及总胆固醇/HDL胆固醇比值是多变量分析中显著的MACE危险因素。
- 治疗24周后HDL胆固醇升高与未来MACE风险降低相关,而LDL或总胆固醇变化无此关联。
核心结论
- 在托法替布治疗24周后,高密度脂蛋白胆固醇升高而非低密度脂蛋白或总胆固醇升高,似乎与未来MACE风险降低相关。
- 基线年龄、高血压和总胆固醇/HDL胆固醇比值与MACE风险显著相关。
研究设计与样本
- 汇总6项III期和2项长期扩展研究中接受至少1个剂量托法替布治疗的中重度活动性类风湿关节炎患者数据,随访7年。
- MACE由独立裁定,采用Cox回归模型评估基线变量与首次MACE时间的关联。
主要发现
- 单变量分析中,传统心血管危险因素及糖皮质激素和他汀使用与MACE风险相关,疾病活动度和炎症指标未显示关联。
- 多变量分析中,基线年龄、高血压和总胆固醇/HDL胆固醇比值仍与MACE风险显著相关。
- 治疗24周后,HDL胆固醇升高和总胆固醇/HDL胆固醇比值下降与MACE风险降低相关;总胆固醇、LDL胆固醇和疾病活动度指标变化未显示关联。
- 红细胞沉降率升高与未来MACE风险增加呈趋势。
关键数值与推荐
- MACE定义:心肌梗死、卒中、心血管死亡。
临床怎么用
- 对接受托法替布治疗的类风湿关节炎患者,应关注基线年龄、高血压及总胆固醇/HDL胆固醇比值等传统心血管危险因素。
- 治疗24周后HDL胆固醇升高可能与未来MACE风险降低相关,但需进一步数据验证托法替布的心血管安全性。
局限性
- 本研究为事后分析(post hoc analysis)。
- 需要进一步数据检验托法替布的心血管安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely active RA receiving ≥1 tofacitinib dose in 6 phase III and 2 long-term extension studies over 7 years. MACE (myocardial infarction, stroke, cardiovascular death) were independently adjudicated. Cox regression models were used to evaluate associations between baseline variables and time to first MACE. Following 24 weeks of tofacitinib, changes in variables and time to future MACE were evaluated after adjusment for age, baseline values, and time-varying tofacitinib dose. Hazard ratios and 95% confidence intervals were calculated. RESULTS: Fifty-two MACE occurred in 4,076 patients over 12,873 patient-years of exposure (incidence rate 0.4 patients with events per 100 patient-years). In univariable analyses of baseline variables, traditional cardiovascular risk factors and glucocorticoid and statin use were associated with MACE risk; disease activity and inflammation measures were not. In subsequent multivariable analyses, baseline age, hypertension, and the total cholesterol to high-density lipoprotein (HDL) cholesterol ratio remained significantly associated with risk of MACE. After 24 weeks of treatment, an increase in HDL cholesterol and a decrease in the total to HDL cholesterol were associated with decreased MACE risk; changes in total cholesterol, low-density lipoprotein (LDL) cholesterol, and disease activity measures were not. Increased erythrocyte sedimentation rates trended with increased future MACE risk. CONCLUSION: In this post hoc analysis, after 24 weeks of tofacitinib treatment, increased HDL cholesterol, but not increased LDL cholesterol or total cholesterol, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.
引用
- Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 31385441. doi:10.1002/art.40911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。